News - tozadenant

Filter

Current filters:

tozadenant

Popular Filters

Biotie completes planned portfolio review

Biotie completes planned portfolio review

24-09-2013

Biotie Therapies has revealed the outcome of its planned portfolio review, following its success earlier…

Biotie TherapiesLicensingLundbeckNeurelisNeurologicalNRL-1PharmaceuticalResearchSelincrotozadenantUCB

UCB licenses global rights to tozadenant in Parkinson's disease from Biotie

27-02-2013

Finland-based Biotie Therapies (Nasdaq-OMX: BTH1V) says that UCB (Euronext Brussels; UCB), Belgium's…

Biotie TherapiesLicensingNeurologicalPharmaceuticaltozadenantUCB

Biotie assets available for partnering; update on tozadenant

08-07-2012

Finland-based biotech firm Biotie Therapies' (OMX: BTH1V) retention of SYN120 rights after Roche decided…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckNeurologicalResearchSelincroSYN120tozadenantUCB

Back to top